NEW YORK, Feb. 6 /PRNewswire/ -- Over the past few years, the strategic importance of the global pharmaceutical marketplace has become increasingly apparent. Multinational interest and investment in the global pharmaceutical industry is at an all-time high and competition is heating up. On one hand big pharma is pumping in more resources into outsourcing and offshoring. On the other hand, drug safety issues, threat from biogenerics, stricter protocols for APIs and pharmacovigilance issues question some existing models and frameworks. More than ever, as the demand intensifies to fill the pharmaceutical pipeline with new drugs and therapeutics -- outsourcing partnerships are playing an increasingly critical role.
The 2008 BioPharma Outsourcing: Partnerships with CROs and Other
Service Providers forum, scheduled for March 25-26, 2008 at the Hilton
Boston Back Bay in Boston, MA is designed to bring together pharma and
biotech executives from around the world to gather strategic information
and creating networking relationships all eager to facilitate new
investments and partnerships.
Distinguished Speaker Roster Includes (updated as of February 6, 2008):
-- Diana M. Galer Ph.D., VP, Strategic Management Group, Pfizer Global
Research & Development
-- Mark Tracy, Senior Director, Pharmaceutical Operations, Alnylam
-- RoseAnn Price, Alliance Management, Amgen
-- Mel Sorensen, M.D., President & CEO, Ascenta Therapeutics, Inc.
-- Ahsan Awan, JD, MBA, CRCP, Global CINRG, Inc.
-- Gur Roshwalb, MD, VP & Senior Analyst Health Care, Piper Jaffray
-- Han Gunn, Preclinical Director, Department of Pharmacokinetics & Drug
-- Partha S. Ray, MD, CEO, IndusPharma Consulting Group
-- Michael Palladino, PhD, Senior VP, CTO, & Scientific Co-Founder,
-- Steve J. Bannister, PhD, Chief Scientific Officer, Xcelience, LLC
-- Judd Berman, PhD., Chief Scientific Officer, Dalton Medicinal
-- Zhengming (Jimmy) Chen, PhD, Senior Director, Chemistry and CMC,
DOV Pharmaceutical, Inc.
-- John Lemelan, General Partner, Riverside Partners
-- Dean Wilson, PhD, Research Fellow, Vertex Pharmaceuticals
-- John Maclennan, PhD, Director, Business Development, Wolfe
For Complete List of Speakers, Detailed Agenda, and to Register:
Copyright©2008 PR Newswire.
All rights reserved